Breaking News Instant updates and real-time market news.

KURA

Kura Oncology

$6.55

-2.55 (-28.02%)

22:32
08/10/17
08/10
22:32
08/10/17
22:32

Kura Oncology 7.7M share Secondary priced at $6.50

The deal size was increased to 7.7M shares from 5.3M shares. Leerink and Cowen acted as joint book running managers for the offering.

  • 11

    Aug

KURA Kura Oncology
$6.55

-2.55 (-28.02%)

10/13/16
LEER
10/13/16
INITIATION
Target $15
LEER
Outperform
Kura Oncology reinstated with an Outperform at Leerink
Leerink analyst Jonathan Chang resumed coverage of Kura Oncology with an Outperform rating and $15 price target, saying he views it as "attractively valued" heading into data rich 2017.
08/08/17
SBSH
08/08/17
NO CHANGE
Target $13
SBSH
Buy
Kura Oncology Phase 2 trial update 'encouraging,' says Citi
Citi analyst Joel Beatty views Kura Oncology's Phase 2 HRAS mutant SCCHN trial update as "encouraging." Though the number of patients is still small, the 60% partial response rate is higher than the 13%-16% rate seen historically with approved agents in the squamous cell carcinomas of the head and neck setting, Beatty tells investors in a research note. He raised his price target for Kura shares to $13 from $12 and keeps a Buy rating on the name.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.